B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
复制标题
DOI：
10.1016/j.ebiom.2021.103539
复制
发表时间：
2021-08
期刊：
影响因子：
11.1
通讯作者：
Moschen AR
中科院分区：
文献类型：
--
作者：
Zollner A;Watschinger C;Rössler A;Farcet MR;Penner A;Böhm V;Kiechl SJ;Stampfel G;Hintenberger R;Tilg H;Koch R;Antlanger M;Kreil TR;Kimpel J;Moschen AR
近几个月来，许多医疗保健专业人士在工作场所收购了新冠肺炎，导致医护人员严重短缺。我们调查了之前的新冠肺炎如何影响SARS-CoV-2疫苗接种，以及这些知识如何促进节俭的疫苗接种策略。在41名有SARS-CoV-2感染史(n=14)和无SARS-CoV-2感染史(n=27)的医护人员队列中，我们评估了接种BNT162b2疫苗前、中和后的免疫状态。用受体结合区酶联免疫吸附试验和不同的SARS-CoV-2野生型和伪型病毒中和试验评估体液免疫应答。用干扰素-γ释放试验和细胞内流式细胞术检测T细胞对SARS-CoV-2表面和核衣壳多肽的免疫应答。疫苗相关的副作用被捕获。在新冠肺炎之前，B和T细胞室的疫苗反应都得到了改善。在既往有新冠肺炎史的疫苗接受者中，第一剂疫苗接种后诱导的抗体浓度与血清阴性疫苗接受者在两次注射后相当。这转化为更有效地中和病毒颗粒，甚至比RBD酶联免疫吸附试验结果预期的更明显。此外，在恢复期，T细胞的反应更强，尤其是对SARS-CoV-2核衣壳蛋白的反应特别强。在此，我们证实了最近的发现，即在恢复期，单一剂量的疫苗足以促进SARS-CoV-2在体外的充分中和，因此可能足以诱导对严重新冠肺炎的足够保护。新的尖峰突变病毒变异体使高度保守的核衣壳蛋白--引发强烈的SARS-CoV-2特异性T细胞免疫--成为有趣的额外疫苗靶点。约翰斯·开普勒大学林茨基督教多普勒研究协会
In recent months numerous health care professional acquired COVID-19 at the workplace resulting in significant shortages in medical and nursing staff. We investigated how prior COVID-19 affects SARS-CoV-2 vaccination and how such knowledge could facilitate frugal vaccination strategies. In a cohort of 41 healthcare professionals with (n=14) and without (n=27) previous SARS-CoV-2 infection, we assessed the immune status before, during and after vaccination with BNT162b2. The humoral immune response was assessed by receptor binding domain ELISA and different SARS-CoV-2 neutralisation assays using wildtype and pseudo-typed viruses. T cell immunity against SARS-CoV-2 surface and nucleocapsid peptides were studied using interferon-γ release assays and intracellular flow cytometry. Vaccine-related side effects were captured. Prior COVID-19 resulted in improved vaccine responses both in the B and T cell compartment. In vaccine recipients with prior COVID-19, the first vaccine dose induced high antibody concentrations comparable to seronegative vaccine recipients after two injections. This translated into more efficient neutralisation of virus particles, even more pronounced than expected from the RBD ELISA results. Furthermore, T cell responses were stronger in convalescents and particularly strong against the SARS-CoV-2 nucleocapsid protein. Herein, we corroborate recent findings suggesting that in convalescents a single vaccine dose is sufficient to boost adequate in vitro neutralisation of SARS-CoV-2 and therefore may be sufficient to induce adequate protection against severe COVID-19. New spike mutated virus variants render the highly conserved nucleocapsid protein – eliciting strong SARS-CoV-2 specific T cell immunity – an interesting additional vaccine target. Christian Doppler Research Association, Johannes Kepler University Linz
登录
查看更多内容
影响因子：
82.9
作者：
Levine-Tiefenbrun, Matan;Yelin, Idan;Kishony, Roy
通讯作者：
Kishony, Roy
影响因子：
7.3
作者：
Lim MQ;Kumaran EAP;Tan HC;Lye DC;Leo YS;Ooi EE;MacAry PA;Bertoletti A;Rivino L
通讯作者：
Rivino L
DOI：
10.1016/s2213-2600(21)00068-0
发表时间：
2021-03
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Mehta S;Machado F;Kwizera A;Papazian L;Moss M;Azoulay É;Herridge M
通讯作者：
Herridge M
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
影响因子：
9.4
作者：
Dijkman, Ronald;Jebbink, Maarten F.;van der Hoek, Lia
通讯作者：
van der Hoek, Lia